411 related articles for article (PubMed ID: 27832958)
21. HIF-prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolism.
Haase VH
Hemodial Int; 2017 Jun; 21 Suppl 1(Suppl 1):S110-S124. PubMed ID: 28449418
[TBL] [Abstract][Full Text] [Related]
22. Hypoxia-adaptive pathways: A pharmacological target in fibrotic disease?
Strowitzki MJ; Ritter AS; Kimmer G; Schneider M
Pharmacol Res; 2019 Sep; 147():104364. PubMed ID: 31376431
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of prolyl hydroxylases alters cell metabolism and reverses pre-existing diastolic dysfunction in mice.
He X; Zeng H; Roman RJ; Chen JX
Int J Cardiol; 2018 Dec; 272():281-287. PubMed ID: 30177233
[TBL] [Abstract][Full Text] [Related]
24. Hearts of hypoxia-inducible factor prolyl 4-hydroxylase-2 hypomorphic mice show protection against acute ischemia-reperfusion injury.
Hyvärinen J; Hassinen IE; Sormunen R; Mäki JM; Kivirikko KI; Koivunen P; Myllyharju J
J Biol Chem; 2010 Apr; 285(18):13646-57. PubMed ID: 20185832
[TBL] [Abstract][Full Text] [Related]
25. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors and Iron Metabolism.
Ogawa C; Tsuchiya K; Maeda K
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769359
[TBL] [Abstract][Full Text] [Related]
26. Hypoxia-inducible factor stabilizers for treating anemia of chronic kidney disease.
Hasegawa S; Tanaka T; Nangaku M
Curr Opin Nephrol Hypertens; 2018 Sep; 27(5):331-338. PubMed ID: 30067604
[TBL] [Abstract][Full Text] [Related]
27. Prolyl 4-hydroxylases, key enzymes in the synthesis of collagens and regulation of the response to hypoxia, and their roles as treatment targets.
Myllyharju J
Ann Med; 2008; 40(6):402-17. PubMed ID: 19160570
[TBL] [Abstract][Full Text] [Related]
28. HIF stabilizers in the management of renal anemia: from bench to bedside to pediatrics.
Kular D; Macdougall IC
Pediatr Nephrol; 2019 Mar; 34(3):365-378. PubMed ID: 29569190
[TBL] [Abstract][Full Text] [Related]
29. Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease.
Kurata Y; Tanaka T; Nangaku M
Curr Opin Nephrol Hypertens; 2020 Jul; 29(4):414-422. PubMed ID: 32452915
[TBL] [Abstract][Full Text] [Related]
30. Investigational hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) for the treatment of anemia associated with chronic kidney disease.
Del Vecchio L; Locatelli F
Expert Opin Investig Drugs; 2018 Jul; 27(7):613-621. PubMed ID: 29975110
[TBL] [Abstract][Full Text] [Related]
31. Activation of hypoxia response in endothelial cells contributes to ischemic cardioprotection.
Kerkelä R; Karsikas S; Szabo Z; Serpi R; Magga J; Gao E; Alitalo K; Anisimov A; Sormunen R; Pietilä I; Vainio L; Koch WJ; Kivirikko KI; Myllyharju J; Koivunen P
Mol Cell Biol; 2013 Aug; 33(16):3321-9. PubMed ID: 23775121
[TBL] [Abstract][Full Text] [Related]
32. NADPH oxidase-mitochondria axis-derived ROS mediate arsenite-induced HIF-1α stabilization by inhibiting prolyl hydroxylases activity.
Li YN; Xi MM; Guo Y; Hai CX; Yang WL; Qin XJ
Toxicol Lett; 2014 Jan; 224(2):165-74. PubMed ID: 24188932
[TBL] [Abstract][Full Text] [Related]
33. Changes in Hypoxia-Inducible Factor-1 (HIF-1) and Regulatory Prolyl Hydroxylase (PHD) Enzymes Following Hypoxic-Ischemic Injury in the Neonatal Rat.
Chu HX; Jones NM
Neurochem Res; 2016 Mar; 41(3):515-22. PubMed ID: 26108712
[TBL] [Abstract][Full Text] [Related]
34. Photoactivatable Prolyl Hydroxylase 2 Inhibitors for Stabilizing the Hypoxia-Inducible Factor with Light.
Li Z; Su K; Jiang Z; Yu Y; You Q; Zhang X
J Med Chem; 2019 Aug; 62(16):7583-7588. PubMed ID: 31244107
[TBL] [Abstract][Full Text] [Related]
35. The hypoxia-inducible factor pathway, prolyl hydroxylase domain protein inhibitors, and their roles in bone repair and regeneration.
Fan L; Li J; Yu Z; Dang X; Wang K
Biomed Res Int; 2014; 2014():239356. PubMed ID: 24895555
[TBL] [Abstract][Full Text] [Related]
36. HIF prolyl hydroxylase inhibitors for anemia.
Muchnik E; Kaplan J
Expert Opin Investig Drugs; 2011 May; 20(5):645-56. PubMed ID: 21406036
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of prolyl hydroxylases increases hepatic insulin and decreases glucagon sensitivity by an HIF-2α-dependent mechanism.
Riopel M; Moon JS; Bandyopadhyay GK; You S; Lam K; Liu X; Kisseleva T; Brenner D; Lee YS
Mol Metab; 2020 Nov; 41():101039. PubMed ID: 32534258
[TBL] [Abstract][Full Text] [Related]
38. Preconditioned suppression of prolyl-hydroxylases attenuates renal injury but increases mortality in septic murine models.
Schindler K; Bondeva T; Schindler C; Claus RA; Franke S; Wolf G
Nephrol Dial Transplant; 2016 Jul; 31(7):1100-13. PubMed ID: 26908768
[TBL] [Abstract][Full Text] [Related]
39. Changes in Metabolomic Profiles Induced by Switching from an Erythropoiesis-Stimulating Agent to a Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor in Hemodialysis Patients: A Pilot Study.
Watanabe K; Sato E; Mishima E; Moriya S; Sakabe T; Sato A; Fujiwara M; Fujimaru T; Ito Y; Taki F; Nagahama M; Tanaka K; Kazama JJ; Nakayama M
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37628932
[TBL] [Abstract][Full Text] [Related]
40. Hypoxia-Inducible Factor-Prolyl Hydroxylase Domain Inhibitors to Treat Anemia in Chronic Kidney Disease.
Sakashita M; Tanaka T; Nangaku M
Contrib Nephrol; 2019; 198():112-123. PubMed ID: 30991411
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
